Adicet Bio

Update in progress

ACET (NasdaqCM)

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. Its lead candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy with a CAR targeting CD20 for autoimmune indications. It also develops ADI-212, a gene-edited, armored therapy targeting PSMA. Founded in 2014 and based in Boston, MA.